Y-mAbs Initiates Rolling Submission of Biologics License Application to FDA for Naxitamab for Treatment of Neuroblastoma
Y-mAbs Therapeutics, a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced that it has submitted to the U.S. Food and Drug Administration (“FDA”) the first portions of